University of California, San Francisco Scientific Study: BetterMAN Traditional Chinese Medicine (TCM) Formula Improves Erectile Function in Rats—Rules Out Placebo Effect
The first scientific evidence of the beneficial effects of BetterMAN on penile tissue was published in the prestigious Journal of Urology (November 2000). The JU article reported on a study conducted by leading urologist, Tom Lue, MD at the University of California San Francisco, Department of Urology.
Read the abstract, or view the full article below.
Dr. Lue, known throughout the world for his influential research in the field of impotency, wondered if any of the herbal dietary supplement formulas which claimed to improve ED actually worked. Dr. Lue was intrigued by the reported positive clinical outcomes of BetterMAN. He and his colleagues set out to see if it indeed worked, and if there was a scientific basis for its purported benefits. According to Dr. Lue, “The effectiveness of a product for ED can be ascertained more accurately in animals than in humans due to the absence of the placebo effect, which can run as high as 40% in human studies.”
With this in mind, Dr. Lue conducted his study with hypercholesterolemic rats. Hypercholesterolemia is a factor known to contribute to ED in men. Rats naturally develop ED around the age of 24 months, which is equivalent to 70 human years. Previous research found that rats consistently develop ED after being fed a 1% cholesterol diet for 4 months.
Accordingly, rats in this study were fed a 1% cholesterol diet for 4 months. During the last two-month period, two groups of rats were fed the BetterMAN formula in their drinking water at two different dosages: 25 mg/kg per day and 50 mg/kg per day, while one group was fed water only. A separate control group of rats was fed a normal diet. At the end of the 4 months, 100% of the BetterMAN-treated rats regained their erectile function as evidenced by the normal peak-sustained intracavernous pressure, while all the rats in the non-treated groups remained impotent.
The groups receiving the BetterMAN formula showed no significant difference in cholesterol levels, systolic blood pressure, and neuronal and endothelial nitric oxide synthase (NOS) levels compared to the control groups. The most interesting results were the significant increases in membrane caveolae, caveolin-1, and basic fibroblastic growth factor (bFGF) protein levels in the penile tissue of the BetterMAN-treated groups.
Caveolin-1 is the major component of caveolae, small bulb-shaped invaginations at or near the cell surface, which act to sequester membrane-bound ligands away from extra cellular space and facilitate their delivery to the cell cytoplasm. UCSF researchers suggest that the substantial increases of caveolin-1 and caveolae may compensate or overcome the harmful effects of hypercholesterolemia on the smooth muscle and endothelial cells, and thus, reverse erectile dysfunction in the treated groups.
Basic fibroblastic growth factor (bFGF) protein level was also significantly higher in the BetterMAN-treated group as revealed by Western blot. This finding suggests that treatment with BetterMAN results in up-regulation of bFGF, which may reverse the suppressive effect of hypercholesterolemia on the smooth muscle and endothelium.
The significance of this study is that it rules out the placebo effect. The study also indicates that the activities of BetterMAN are very different from that of PDE-5 inhibitors, such as Viagra. Dr. Lue and his colleagues concluded that it is likely that more factors may be involved in the formula’s ability to treat ED, and that larger scale studies are needed to determine the mechanisms of action of the formula and its effect on other organ systems.